Last updated 19 days ago

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

60 patients around the world

Available in Brazil

Bristol-Myers Squibb

60Patients around the world

This study is for people with

Arthritis

Psoriasic arthritis

Requirements for the patient

To 17 Years

All Gender

Medical requirements

: Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
Participants must have at least three joints that are affected by arthritis.
Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.

: Participants must not have been diagnosed with JPsA before 5 years of age.
Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA.
Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
Other protocol-defined Inclusion/Exclusion criteria apply.

SponsorBristol-Myers Squibb

Study typeInterventional

Conditions

Psoriasic arthritis

Requirements

To 17 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06869551